Caladrius Biosciences (NASDAQ:CLBS) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.36) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.56) by $0.20, Fidelity Earnings reports.
Shares of NASDAQ CLBS traded down $0.68 during trading on Friday, reaching $4.53. The stock had a trading volume of 21,628 shares, compared to its average volume of 36,147. Caladrius Biosciences has a one year low of $2.91 and a one year high of $11.65. The company has a market capitalization of $47.56 million, a price-to-earnings ratio of -2.54 and a beta of 1.22.
A number of equities research analysts have recently weighed in on the company. Zacks Investment Research upgraded Caladrius Biosciences from a “hold” rating to a “buy” rating and set a $6.25 price target for the company in a report on Wednesday, September 12th. HC Wainwright boosted their price target on Caladrius Biosciences to $15.00 and gave the company a “buy” rating in a report on Monday, September 10th. Finally, Chardan Capital reiterated a “buy” rating on shares of Caladrius Biosciences in a report on Wednesday, August 29th.
Caladrius Biosciences Company Profile
Caladrius Biosciences, Inc operates as a global healthcare company, which engages in developing cellular therapies that repair damaged tissue, cells and organs and restore their normal function. It is pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease.
Featured Story: How to Use a Moving Average for Trading
Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.